These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38898427)

  • 1. Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS- real-world data.
    Schönfelder K; Kühne L; Schulte-Kemna L; Kaufeld J; Rohn H; Kribben A; Schröppel B; Brinkkötter PT; Gäckler A
    BMC Nephrol; 2024 Jun; 25(1):202. PubMed ID: 38898427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis.
    Gäckler A; Schönermarck U; Dobronravov V; La Manna G; Denker A; Liu P; Vinogradova M; Yoon SS; Praga M
    BMC Nephrol; 2021 Jan; 22(1):5. PubMed ID: 33407224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome.
    Mauch TJ; Chladek MR; Cataland S; Chaturvedi S; Dixon BP; Garlo K; Gasteyger C; Java A; Leguizamo J; Lloyd-Price L; Pham TP; Symonds T; Tomazos I; Wang Y
    J Comp Eff Res; 2023 Sep; 12(9):e230036. PubMed ID: 37515502
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
    Ariceta G; Dixon BP; Kim SH; Kapur G; Mauch T; Ortiz S; Vallee M; Denker AE; Kang HG; Greenbaum LA;
    Kidney Int; 2021 Jul; 100(1):225-237. PubMed ID: 33307104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab.
    Schaefer F; Al-Dakkak I; Anokhina K; Cohen D; Greenbaum LA; Ariceta G
    Kidney Int Rep; 2024 Sep; 9(9):2648-2656. PubMed ID: 39291212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.
    Tanaka K; Adams B; Aris AM; Fujita N; Ogawa M; Ortiz S; Vallee M; Greenbaum LA
    Pediatr Nephrol; 2021 Apr; 36(4):889-898. PubMed ID: 33048203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions for atypical haemolytic uraemic syndrome.
    Pugh D; O'Sullivan ED; Duthie FA; Masson P; Kavanagh D
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD012862. PubMed ID: 33783815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience.
    Kant S; Bhalla A; Alasfar S; Alachkar N
    BMC Nephrol; 2020 May; 21(1):189. PubMed ID: 32434487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
    Rondeau E; Scully M; Ariceta G; Barbour T; Cataland S; Heyne N; Miyakawa Y; Ortiz S; Swenson E; Vallee M; Yoon SS; Kavanagh D; Haller H;
    Kidney Int; 2020 Jun; 97(6):1287-1296. PubMed ID: 32299680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome.
    Wang Y; Johnston K; Popoff E; Myren KJ; Cheung A; Faria C; Tomazos I
    J Med Econ; 2020 Dec; 23(12):1503-1515. PubMed ID: 33001704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F; Hourmant M; Campistol JM; Cataland SR; Espinosa M; Gaber AO; Menne J; Minetti EE; Provôt F; Rondeau E; Ruggenenti P; Weekers LE; Ogawa M; Bedrosian CL; Legendre CM
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
    Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome.
    Syed YY
    Drugs; 2021 Apr; 81(5):587-594. PubMed ID: 33738756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials.
    Dixon BP; Kavanagh D; Aris ADM; Adams B; Kang HG; Wang E; Garlo K; Ogawa M; Amancha P; Chakravarty S; Heyne N; Kim SH; Cataland S; Yoon SS; Miyakawa Y; Luque Y; Muff-Luett M; Tanaka K; Greenbaum LA
    Kidney Med; 2024 Aug; 6(8):100855. PubMed ID: 39105067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data.
    Tomazos I; Hatswell AJ; Cataland S; Chen P; Freemantle N; Lommele Å; Deighton K; Knowles E; Sheerin NS; Rondeau E
    Clin Nephrol; 2022 May; 97(5):261-272. PubMed ID: 34931610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ravulizumab facilitates reduced burden of vascular access, a major benefit in paediatric atypical haemolytic uraemic syndrome.
    Bleathman F; Kausman JY; Hosking LM; Forbes TA
    J Paediatr Child Health; 2024 Jun; 60(6):183-187. PubMed ID: 38661088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Ariceta G
    Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
    Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.